Nicox names Damian Marron as Chair and Marc Le Bozec as Director

Nicox SA, an international ophthalmology company based in Sophia Antipolis, France, has announced new leadership appointments. Damian Marron, a highly experienced healthcare executive, has been appointed as Chair of the Board of Directors. Additionally, Marc Le Bozec, an accomplished life sciences entrepreneur, has been named a new Director. Both Marron and Le Bozec are recognized as independent Directors according to the Middlenext Governance Code.

The changes come as Jean-François Labbe retires from his role as Chair and member of the Board, having completed his term. Les Kaplan has also decided to step down from the Board after years of committed service. Both Labbe and Kaplan have been integral to Nicox's journey, and their contributions have been highly valued by the company.

Gavin Spencer, Chief Executive Officer of Nicox, expressed his enthusiasm for the new appointments. He highlighted that Marron and Le Bozec bring substantial expertise that aligns with Nicox's current strategic and developmental goals. Their roles will be pivotal in exploring strategic options, financing opportunities, and advancing business development discussions, particularly concerning NCX 470 and other drug candidates.

Damian Marron, upon his appointment, stated his excitement about joining Nicox during this crucial phase. He emphasized the strategic and business development opportunities available to the company over the next 12-18 months, given its current revenue and late-stage asset. Marron looks forward to collaborating with fellow board members to support the company's growth and development.

Marron brings a wealth of experience to Nicox, having served in various executive roles including CEO, Chair, non-executive Board Member, and company advisor. His expertise spans public funding, venture capital, portfolio planning, mergers and acquisitions, and license agreements. He has a strong background in immuno-oncology, cellular therapy, and orphan diseases. Marron is also Chair of the Board for Circio Holding ASA, Imophoron Ltd, and Indegra Therapeutics Ltd.

Marc Le Bozec also brings notable experience in life sciences and finance. As the CFO of Cellectis, he managed its IPO in Paris and successfully raised €120 million. He later transitioned Cytoo towards human muscle research, securing FDA validation and becoming a key shareholder. Le Bozec has also worked as a professional investor and fund manager at Financière Arbevel and recently founded Neurodyx to advance neuro-inflammation research.

With these new appointments, Nicox's Board of Directors now comprises Damian Marron as Chair and Independent Director, Gavin Spencer as Chief Executive Officer and Director, Michele Garufi as Co-Founder and Director, and Marc Le Bozec as Independent Director.

Nicox SA focuses on developing innovative solutions to help maintain vision and improve ocular health. Its leading clinical development program, NCX 470, is a novel nitric oxide-donating bimatoprost eye drop aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company generates revenue from VYZULTA® for glaucoma and ZERVIATE® for allergic conjunctivitis, through various licensing agreements. Nicox is listed on Euronext Growth Paris under the ticker symbol ALCOX and is included in the CAC Healthcare index.